Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial

Vanita R. Aroda(Brigham and Women's Hospital), Richard M. Bergenstal(HealthPartners), Elisabeth Niemoeller(Sanofi (Germany)), Carol Wysham(Rockwood Clinic), Elisabeth Souhami(Sanofi (France)), Jeffrey Unger(Catalina Research Institute), Julio Rosenstock(Velocity Clinical Research (United States)), Hailing Guo(Biostatistical Consulting (United States)), Diego Bellido(Complexo Hospitalario Universitario A Coruña), Guillermo González-Gálvez(Universidad de Guadalajara)
Diabetes Care
September 20, 2016
10.2337/dc16-1495
Cited by 254

Related Papers

Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
|Diabetes Care|2019|3.8k
2. Classification and Diagnosis of Diabetes:<i>Standards of Care in Diabetes—2023</i>
|Diabetes Care|2022|2.4k
International Consensus on Use of Continuous Glucose Monitoring
|Diabetes Care|2017|2k
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
|Diabetes Care|2022|1.9k
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
|Diabetologia|2022|986